Loading stock data…
TWST
$60.40+1.95 (+3.34%)
Market ClosedLast close May 1
Twist Bioscience Corporation manufactures and sells synthetic DNA-based products.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Twist Bioscience Corporation in the Healthcare sector is trading at $60.40. The stock is currently near its 52-week high of $66.06, remaining 61.2% above its 200-day moving average. Technical signals show neutral RSI of 67 and bearish MACD signal, explaining why TWST maintains its current momentum and trend strength. The Whystock Score of 75/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Overbought levels (RSI 67) — risk of consolidation or pullback
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$60.40
Potential Upside
5%
Whystock Fair Value$63.42
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, an...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$3.87B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.21
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-16.79%
Volume
Today's trading volume
2.72M
Recent News
Assessing Twist Bioscience (TWST) Valuation After Insider Sale And Recent Q1 FY26 Optimism
Twist Bioscience (TWST) stock came under pressure after Senior Vice President of Human Resources Paula Green sold more than 39,400 shares for nearly US$2.1 million, following a strong year to date rally. See our latest analysis for Twist Bioscience. The recent insider sale comes after a strong year to date share price return of 53.07% and a 56.40% 3 month share price return, alongside the Invenra licensing agreement and upbeat Q1 FY26 guidance. At the same time, the 1 year total shareholder...
Twist Bioscience Adds Invenra Bispecific Platform To Broaden Discovery Opportunity
Twist Bioscience (NasdaqGS:TWST) entered a licensing agreement with Invenra Inc. to co-exclusively provide Invenra's B-Body bispecific antibody platform. The deal broadens Twist's antibody discovery offerings across in vivo, in vitro, and AI-enabled workflows. Twist also gains a direct ownership stake in Invenra and potential future revenue participation from bispecific discovery services and licensing. For you as an investor, this move adds another building block to Twist Bioscience's role...
Biotech Beat Nvidia in 2025. Can It Do It Again?
Big pharma and biotech take the earnings stage with reports from Eli Lilly and Novo Nordisk leading the lineup. Will they help the industry once again outperform AI champ Nvidia?
Twist Bioscience Annual Meeting: Shareholders Elect Directors, Approve Pay and EY Auditor Ratification
Twist Bioscience (NASDAQ:TWST) held its 2026 annual meeting of stockholders via an online webcast, with Lead Independent Director Robert Chess serving as chairman. The meeting focused on three standard items of corporate governance: electing directors, conducting a non-binding advisory vote on execu
Twist Bioscience Guidance Lift Puts AI Demand And Risks In Focus
Twist Bioscience (NasdaqGS:TWST) raised its full year revenue guidance, reflecting updated expectations for its business in synthetic DNA and protein solutions. The company highlighted strong demand for its AI enabled DNA and protein platforms, supported by expanding collaborations across discovery and research. Twist Bioscience also announced significant inducement equity awards tied to recent hires, aimed at supporting ongoing growth initiatives. Twist Bioscience, trading at $48.12, has...